Publications by authors named "Frederick L Hall"

Claim this Profile
G
Gene and Cell Therapy for Sarcomas: A Review.
Sant P Chawla, Skyler S Pang, Darshit Jain, Samantha Jeffrey, Neal S Chawla, Frederick L Hall

Cancers (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Celebrating the 200th mendel's anniversary: gene-targeted diagnostics and therapies for cancer.
Noah Federman, Erlinda M Gordon, Sant P Chawla, Frederick L Hall

Front Mol Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Mendel to Gene Therapy.
Samantha L Jeffrey, Don A Brigham, Sant P Chawla, Noah Federman, Frederick L Hall

Anticancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-stage + HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a Inhibitor.
Sant P Chawla, Olga Olevsky, Geeta Iyengar, Don A Brigham, Nadezhda Omelchenko, Frederick L Hall

Anticancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The advent of a pan-collagenous CLOVIS POINT for pathotropic targeting and cancer gene therapy, a retrospective.
Erlinda M Gordon, Frederick L Hall

Front Mol Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130).
Sant P Chawla, Steven Wong, Doris Quon, Ania Moradkhani, Victoria S Chua, Frederick L Hall

Front Mol Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review.
Michael A Morse, Sant P Chawla, Terence Z Wong, Howard W Bruckner, Frederick L Hall

Mol Clin Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.
Sant P Chawla, Howard Bruckner, Michael A Morse, Nupur Assudani, Frederick L Hall

Mol Ther Oncolytics· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting Oncogenic Drivers along the Pathway for Cancer Therapy and Gene Therapy.
Ahmad Al-Shihabi, Sant P Chawla, Frederick L Hall, Erlinda M Gordon

Mol Ther Oncolytics· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.
Erlinda M Gordon, Joshua R Ravicz, Seiya Liu, Sant P Chawla, Frederick L Hall

Mol Clin Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rexin-G, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report.
Seth Kim, Noah Federman, Erlinda M Gordon, Frederick L Hall, Sant P Chawla

Mol Clin Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.
Frederick L Hall, John P Levy, Rebecca A Reed, Wasinee N Petchpud, Victoria S Chua

Oncol Rep· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent.
Erlinda M Gordon, Frederick L Hall

Int J Oncol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rexin-G, a targeted genetic medicine for cancer.
Erlinda M Gordon, Frederick L Hall

Expert Opin Biol Ther· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
Sant P Chawla, Victoria S Chua, Lita Fernandez, Dorris Quon, William C Blackwelder, Frederick L Hall

Mol Ther· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.
Sant P Chawla, Victoria S Chua, Lita Fernandez, Doris Quon, Andreh Saralou, Frederick L Hall

Mol Ther· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 'timely' development of Rexin-G: first targeted injectable gene vector (review).
Erlinda M Gordon, Frederick L Hall

Int J Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
Erlinda M Gordon, John P Levy, Rebecca A Reed, W Nina Petchpud, Liqiong Liu, Frederick L Hall

Int J Oncol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.
Erlinda M Gordon, Maria Teresa Chan, Nelson Geraldino, Francisco F Lopez, Gerardo H Cornelio, Frederick L Hall

Int J Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.
Erlinda M Gordon, Francisco F Lopez, Gerardo H Cornelio, Conrado C Lorenzo, John P Levy, Frederick L Hall

Int J Oncol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanotechnology blooms, at last (Review).
Erlinda M Gordon, Frederick L Hall

Oncol Rep· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Erlinda M Gordon, Gerardo H Cornelio, Conrado C Lorenzo, John P Levy, Rebecca A Reed, Frederick L Hall

Int J Oncol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype.
Ghiabe H Guibinga, Frederick L Hall, Erlinda M Gordon, Erkki Ruoslahti, Theodore Friedmann

Mol Ther· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.
Jonathan C Song, Peter J McDonnell, Erlinda M Gordon, Frederick L Hall, W French Anderson

Hum Gene Ther· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis